These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27817860)

  • 41. Long-term therapy with sorafenib is associated with pancreatic atrophy.
    Xu L; Zhou DS; Zhao J; Spolverato G; Zhang YJ; Li SP; Chen MS; Pawlik TM
    J Surg Res; 2015 Dec; 199(2):314-21. PubMed ID: 26115806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of sorafenib-related adverse events: a clinician's perspective.
    Brose MS; Frenette CT; Keefe SM; Stein SM
    Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sorafenib: 10 years after the first pivotal trial.
    Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
    Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
    Di Costanzo GG; de Stefano G; Tortora R; Farella N; Addario L; Lampasi F; Lanza AG; Cordone G; Imparato M; Caporaso N
    Future Oncol; 2015; 11(6):943-51. PubMed ID: 25760975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
    Lv Y; Liang R; Hu X; Liu Z; Liao X; Lin Y; Yuan C; Liao S; Li Q; Zhang J; Li Y
    Pharmazie; 2014 Oct; 69(10):759-63. PubMed ID: 25985566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
    J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
    Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
    [No Abstract]   [Full Text] [Related]  

  • 50. Painful Rashes on the Palms and Soles.
    Bhullar M; Bhullar A; Arachchi NJ
    Ann Acad Med Singap; 2016 Oct; 45(10):479-480. PubMed ID: 27832225
    [No Abstract]   [Full Text] [Related]  

  • 51. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
    Xu L; Wang B; Ding W
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
    [No Abstract]   [Full Text] [Related]  

  • 53. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
    Reig M; Torres F; Rodriguez-Lope C; Forner A; LLarch N; Rimola J; Darnell A; Ríos J; Ayuso C; Bruix J
    J Hepatol; 2014 Aug; 61(2):318-24. PubMed ID: 24703956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
    Zheng SZ; Liu DJ; Sun P; Yu GS; Xu YT; Gong W; Liu J
    World J Gastroenterol; 2014 Nov; 20(43):16275-81. PubMed ID: 25473183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
    Nishikawa H; Osaki Y; Endo M; Takeda H; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
    Int J Oncol; 2014 Dec; 45(6):2295-302. PubMed ID: 25230744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma.
    Mallick R; Cai J; Wogen J
    Curr Med Res Opin; 2013 Dec; 29(12):1701-8. PubMed ID: 24010684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H; Han SH; Kang H; Park K
    Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract]   [Full Text] [Related]  

  • 59. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
    Iavarone M; Cabibbo G; Biolato M; Della Corte C; Maida M; Barbara M; Basso M; Vavassori S; Craxì A; Grieco A; Cammà C; Colombo M
    Hepatology; 2015 Sep; 62(3):784-91. PubMed ID: 25645399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.